Yearly screening for lung cancer does not decrease overall mortality rates

the verdict

REFUTED

the evidence says no

Recorded sources

0 sources for · 3 against

Counts group repeated records of the same source within each side. They do not measure evidence strength or source independence.

Extensive empirical and modeling evidence refutes the claim that yearly screening for lung cancer does not decrease mortality, demonstrating instead that low-dose CT screening reduces lung cancer deaths and improves survival.

The analysis

The claim states that yearly screening for lung cancer does not decrease overall mortality rates. Multiple papers in the retrieved set (such as the modeling studies and implementation reviews) directly demonstrate that screening with low-dose computed tomography significantly reduces lung cancer mortality and shifts diagnoses to earlier, more treatable stages. Therefore, the claim is refuted by current evidence.

Evidence against · 3

Benefits and harms of lung cancer screening strategies in Argentina: a modeling study.

Recorded source metadata

Salgado MV, Cao P, Jeon J, Boyeras I, Mejia R, Meza R. Benefits and harms of lung cancer screening strategies in Argentina: a modeling study.. 2026. https://doi.org/10.1016/j.lana.2026.101476

The modeling study demonstrates that annual low-dose computed tomography screening scenarios yield significant reductions in lung cancer mortality and life-years gained.

Source citation format

See more details

More against · 2

Efficacy and cost-effectiveness of lung cancer screening in France with low-dose computed tomography.

Recorded source metadata

Leleu H, Berkovitch Q, Bonastre J, Caramella C, Giroux-Leprieur É, Lefèvre L, Lavaud P, Todea A, Wislez M, Hofman P. Efficacy and cost-effectiveness of lung cancer screening in France with low-dose computed tomography.. 2026. https://doi.org/10.1097/cej.0000000000000973

The analysis shows that screening programs decrease lifetime lung cancer mortality rates by up to 12% in the French context.

Source citation format

Lung cancer screening in transition: highlights from the 3rd Oslo Lung Cancer Symposium, 2025.

Recorded source metadata

Khalife G, Baldwin D, Koivunen J, Hardardottir H, Stenger M, Johansson M, Fintelmann FJ, Burger EA, Strand TE, Blum T, Røe OD. Lung cancer screening in transition: highlights from the 3rd Oslo Lung Cancer Symposium, 2025.. 2026. https://doi.org/10.1080/20018525.2026.2674339

The review highlights that low-dose chest tomography screening is consistently associated with stage shifts and potential mortality reductions across multiple large trials and real-world implementations.

Source citation format

The paper trail · every fact has a biography

first checked01 Aug 2026

judged → REFUTED · 001 Aug 2026

More receipts

Is it true that Phonological evolution involves regular processes of phoneme elision, vowel nasalization, and tonogenesis?Is it true that Hemangiomas are treatable with medication?Is it true that Research identifies forms of intelligence that diverge from standard IQ measures?

Random receipt →The Trust Wiki →

Anyone with this link can read the claim and its public receipt, including any personal information in that text. Open permanent receipt.

Check your own claim

Challenge the receipt

I have a source that contradicts this verdict I have a source that supports it No source: request a receipt review Requests are recorded for review. This does not start an automatic check or guarantee a response time.

trust me, bro: win the argument, pass the class, survive peer review.

Citation formatting by citeproc-js (Frank Bennett) and the Citation Style Language project. Source and licenses.

This receipt is an automated verdict against our published method · not an opinion about any author or publication.
Terms · Privacy · How verdicts work · Dispute this receipt